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Bryophyllum pinnatum enhances the
inhibitory effect of atosiban and nifedipine
on human myometrial contractility: an
in vitro study
S. Santos1,2, C. Haslinger1, M. Mennet3, U. von Mandach1, M. Hamburger2 and A. P. Simões-Wüst1*
Abstract
Background: The herbal medicine Bryophyllum pinnatum has been used as a tocolytic agent in anthroposophic
medicine and, recently, in conventional settings alone or as an add-on medication with tocolytic agents such as
atosiban or nifedipine. We wanted to compare the inhibitory effect of atosiban and nifedipine on human
myometrial contractility in vitro in the absence and in the presence of B. pinnatum press juice (BPJ).
Methods: Myometrium biopsies were collected during elective Caesarean sections. Myometrial strips were
placed under tension into an organ bath and allowed to contract spontaneously. Test substances alone and
at concentrations known to moderately affect contractility in this setup, or in combination, were added to
the organ bath, and contractility was recorded throughout the experiments. Changes in the strength
(measured as area under the curve (AUC) and amplitude) and frequency of contractions after the addition of
all test substances were determined. Cell viability assays were performed with the human myometrium
hTERT-C3 and PHM1–41 cell lines.
Results: BPJ (2.5 μg/mL), atosiban (0.27 μg/mL), and nifedipine (3 ng/mL), moderately reduced the strength
of spontaneous myometrium contractions. When BPJ was added together with atosiban or nifedipine,
inhibition of contraction strength was significantly higher than with the tocolytics alone (p = 0.03 and p <
0.001, respectively). In the case of AUC, BPJ plus atosiban promoted a decrease to 48.8 ± 6.3% of initial,
whereas BPJ and atosiban alone lowered it to 70.9 ± 4.7% and to 80.9 ± 4.1% of initial, respectively. Also in
the case of AUC, BPJ plus nifedipine promoted a decrease to 39.9 ± 4.6% of initial, at the same time that
BPJ and nifedipine alone lowered it to 78.9 ± 3.8% and 71.0 ± 3.4% of initial. Amplitude data supported those
AUC data. The inhibitory effects of BPJ plus atosiban and of BPJ plus nifedipine on contractions strength
were concentration-dependent. None of the test substances, alone or in combination, decreased myometrial
cell viability.
Conclusions: BPJ enhances the inhibitory effect of atosiban and nifedipine on the strength of myometrial
contractions, without affecting myometrium tissue or cell viability. The combination treatment of BPJ with
atosiban or nifedipine has therapeutic potential.
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Background
Preterm birth, defined as birth before 37 weeks of
pregnancy, affects 5 to 18% of pregnancies. It is the
number one cause of neonatal deaths, and the second
leading cause of childhood death under 5 years of age
[1–3]. Delaying preterm delivery frequently involves
pharmacological inhibition of myometrial contractions
(tocolysis) [4]. The main aim of a tocolytic treatment
is to delay delivery long enough (24–48 h) for cortico-
steroid administration to the mother to achieve foetal
lung maturation, and for transfer of the mother to a
perinatal centre [4, 5]. Several types of tocolytics are
currently in use [4, 6, 7]. Atosiban, a competitive
oxytocin-vasopressin antagonist [8], and nifedipine, a
calcium channel-blocking agent [9], are often given as
first tocolytic treatment since they have good efficacy
to side-effect ratios [10, 11]. A recent randomised
study showed that atosiban and nifedipine resulted in
similar perinatal outcomes [12]. Long term (> 1 week)
tocolysis is seldom pursued and rarely achieved even
though pregnancy prolongation favours perinatal out-
comes [13].
Bryophyllum pinnatum (Lam.) Oken [syn. Kalanchoe
pinnata (Lam.) Pers.; family Crassulaceae] is a perennial
succulent plant that grows widely in tropical and subtrop-
ical areas. In Europe, B. pinnatum started to be used in
anthroposophic medicine [14] as treatment of preterm
labour [15, 16]. Retrospective analyses of the clinical prac-
tice revealed good efficacy of B. pinnatum preparations in
this indication [15, 16], which was corroborated by a
matched pair study [17]. Results of a prospective rando-
mised trial on acute tocolysis are in line with good efficacy,
but have to be interpreted with caution since - due to poor
recruitment rate - the study was discontinued before com-
pletion [18]. All clinical studies demonstrated a very good
tolerability of B. pinnatum. The use of such preparations in
the treatment of pre-term contractions was supported by
in vitro studies [19, 20].
An assessment of the internal treatment recommenda-
tions in the main Swiss obstetrics centres showed that B.
pinnatum preparations are being prescribed for the treat-
ment of preterm contractions [21]. This is in line with a
Swiss online survey which showed that in approximately
¾ of the cases B. pinnatum preparations are administered
in combination with synthetic tocolytics [22]. Comparable
results were obtained in a retrospective analysis of the
clinical practice at the University Hospital Zurich [23]. It
is still not clear how B. pinnatum preparations influence
the effects of tocolytics on myometrial contractility. We
here compare the inhibitory effect of atosiban and nifedi-
pine on human myometrial contractility in vitro in the
absence and in the presence of B. pinnatum press juice
(BPJ). Given a potentially synergistic effect of these sub-
stances, the question is of clinical interest.
Methods
Test substances
B. pinnatum leaves were harvested on the 25 March
2014 from B. pinnatum plants cultivated at the Medical
Plants Garden located in S. Roque, Brazil, and that des-
cend from seedlings brought from Weleda AG, Arlesheim,
Switzerland, in the past. Plant collection did not affect
Brazilian biodiversity and was done in accordance to
Brazilian Environmental and Biodiversity laws, mainly
Provisional Measure 2186–16 from 23 August 2001 that
rules access to genetic resources and traditional know-
ledge. The Medical Plants Garden from S. Roque belongs
to Weleda Brazil and the harvested B. pinnatum plants
were identified by the Weleda employees Moacyr Copani
and Paulo Copani. A voucher specimen ZSS 29717 was
deposited at the Zurich Succulent Plant Collection. Leaves
were sent by airmail to Weleda Arlesheim, Switzerland, in
a refrigerated box. BPJ was obtained by mechanical press-
ing in a roller, the procedure used in the first step of the
production of the active ingredient of Weleda Bryophyl-
lum 50% chewable tablets (Weleda AG, Arlesheim). Unfil-
tered press juice was kept at − 80 °C until use.
Atosiban (Tractocile®, 7.5mg/mL injectable solution), was
purchased from Ferring Pharmaceuticals, Baar, Switzerland.
Nifedipine was obtained from Sigma-Aldrich (purity ≥98%,
N7634-1G); a 3.7 μg/mL stock solution was prepared in
DMSO.
Design
The ethics committee of canton Zurich approved the
study with human myometrium biopsies (KEK-ZH-Nr.
2014–0717, approval date 12.05.2015). Patients were
asked prior to elective caesarean sections to donate a
myometrium biopsy if the following inclusion criteria
were fulfilled: single pregnancy, planned first caesarean
section, negative HIV test, age > 18 years, and no tocoly-
sis within 2 weeks before caesarean section.
A myometrial biopsy of approx. 5 g was taken from each
study participant at the cranial margin of the uterotomy.
The myometrial biopsy was immediately stored in Ringer
solution and transported to the lab. Longitudinal strips of
muscle of about 15 × 2 × 1mm were cut and mounted in a
myograph bath chamber. Each of the four myograph cham-
bers contained 6mL of Krebs solution (in mM: NaCl 118,
NaHCO3 24.9, KCl 4.7, KH2PO4 1.24, CaCl2 2.48, MgSO4
1.21, Glucose 10, EDTA 0.034; pH = 7.4), with temperature
regulated at 37 °C and bubbled with 95% O2 and 5% CO2
(PanGas, Dagmersellen, Switzerland). Contractions were re-
corded with a DMT800MS myograph (Danish Mayo Tech-
nology, Denmark) and transferred to a personal computer
via a transducer (ADInstruments PowerLab 4/30). Myome-
trial strips were allowed to contract spontaneously (which
took in most cases approximately 2 h). During this time,
the Krebs solution was replaced every 30min.
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In preliminary experiments, concentrations of atosiban,
nifedipine and BPJ were determined that would lead to
moderate lowering (by 20–30%) of contraction strength.
These concentrations were used in the main combination
experiments, performed as described below. In prelimin-
ary experiments, two slightly different experimental proto-
cols appeared equally promising. We used both protocols,
one for the experiments with atosiban, and the second for
nifedipine, to find out whether one of the protocols would
result in lower standard error of the means (SEM) values.
Effect of the combination of BPJ with atosiban or with
nifedipine on myometrial contractility
In all cases, regular spontaneous myometrial contractions
in amplitude and frequency were recorded for 30min.
When the effects of the combination of BPJ with atosi-
ban were being studied, each one of four strips was
treated with one test substance, and contractility was
recorded for additional 30 min. Test substances were:
Krebs solution, 5 μL (control; n = 11); BPJ, 15 μL (0.25%
final concentration, corresponding to 2.5 μg/mL; n = 13);
atosiban, 4.3 μL of 375 μg/mL (0.27 μg/mL final concen-
tration; n = 11); and BPJ and atosiban combined (same
concentrations, n = 12). Temporal and vehicle controls
were run in parallel in each experiment to access the
decay in contractility of the myometrium with time.
To study the combination of BPJ with nifedipine, Krebs
solution, 5 μL (control; n = 13) or nifedipine, 5 μL of
3.7 μg/mL (final concentration 3 ng/mL; n = 11) was added
to two chambers each, contractility was recorded for 30
min and thereafter 15 μL of BPJ (final concentration of
0.25 μg/mL; n = 10) was added to all four chambers. This
resulted in two chambers with BPJ alone and two cham-
bers with the combination of nifedipine with BPJ. After
BPJ addition, contractions were recorded for 30min
(Fig. 1b).
Dose-dependency effect of combination treatments on
myometrial contractility
To find out whether the effect of the combination treat-
ments would further increase at higher concentrations, a
previously described approach was followed [24]. In brief,
when spontaneous contractions were regular for 20min,
Krebs solution was added (addition 0), and contractility
was recorded for 20min. Then, each strip was treated with
one test substance by adding 4 times, at time intervals of
20min, the same volume of a stock solution. Test solu-
tions included: control, 5 μL Krebs solution; BPJ, 15 μL;
combination of BPJ (15 μL) plus atosiban (4.3 μL of
375 μg/mL) or BPJ (15 μL) plus nifedipine (5 μL of 3.7 μg/
mL). For each substance tested, 5 different biopsies were
used (n = 5).
Vitality of myometrial strips
The exposure to the different test substances was
followed by a 30-min washing period where Krebs solu-
tion was changed several times (at 5, 10, 20 and 30min).
Vitality of the strips was determined at the end of the
experiment (30 min after washing) by observation of
spontaneous contractions. In all cases, strips were con-
tracting and data were included in the present analysis.
Fig. 1 Experimental design for measurement of myometrial contractions. Test substances were added to the organ bath when myometrium
strips had been contracting regularly for 30 min. When the effects of BPJ and/or atosiban were being studied (a), Krebs solution (control), BPJ,
atosiban, or the combination of BPJ and atosiban were added, and contractility was recorded for 30 min. When the effects of BPJ and/or
nifedipine were being studied (b), Krebs solution (control; two strips) or nifedipine (two strips) was added, contractility was recorded for 30 min,
and then BPJ was added to all chambers. Exposure to test substances was followed by a 30 min washout step, with change of Krebs solution at
5, 10, 20 and 30 min
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Fig. 2 (See legend on next page.)
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Myograph data processing
Myometrium contractions were recorded by LabChart
Pro 8.0.6 (ADInstruments, Germany) and analysed
with the peak analysis module. For each contraction,
the area under the curve (AUC) and the amplitude
were analysed. Depending on the type of experiments,
for each 20 or 30 min interval, the average AUC and
average amplitude were calculated, and the number of
contractions was noted (frequency). Initial values of
AUC, amplitude and frequency of spontaneous con-
tractions (before any addition) were set at 100%.
Effects after addition of test substances were expressed
as percentage of initial. When studying the combin-
ation of BPJ and atosiban and in all dose-dependency
experiments, the values obtained in one strip per bi-
opsy were used for further statistical analyses. When
investigating the combination of BPJ and nifedipine,
two strips per biopsy were used to determine the effect
of each substance (BPJ, nifedipine, BPJ plus nifedipine,
and control). In this case, average values of the two
determinations were calculated and used for further
statistical analyses.
Viability assays in myometrium cell lines
Human myometrial telomerase reverse transcriptase
cell line (hTERT-C3) [25, 26], provided by M. Grãos
(University of Coimbra, Portugal), was cultured in an
1:1 mixture of DMEM and F-12 supplemented with
antibiotics (100 U/mL penicillin and 100 μg/mL strepto-
mycin) and 10% (v/v) heat-inactivated foetal bovine serum
(FBS) (all from Gibco, Paisley, UK). Human uterine myo-
metrium smooth muscle cells (PHM1–41), obtained from
American Type Culture Collection (ATCC® CRL-3046™)
were maintained in ATCC-formulated DMEM (ATCC®
No. 30–2002) supplemented with 0.1mg/mLG-418 (Carl
Roth, Zurich, Switzerland), 2 mM glutamine and 10% (v/
v) heat-inactivated FBS.
hTERT-C3 cells were seeded at a density of 5 × 104
cells/mL (5 × 103 cells per well) and PHM1–41 cells at a
density of 8 × 104 cells/mL (8 × 103 cells per well) into
transparent 96-well microplates. 1 day after seeding, cells
were exposed to BPJ (2.5–10.0 μg/mL), atosiban (0.27–
1.08 μg/mL), nifedipine (3.0–12.0 ng/mL) or the combi-
nations BPJ plus atosiban or BPJ plus nifedipine for 24 h.
After exposure, resazurin (Alamar Blue, Invitrogen, Illkirch
Cedex, France) was added to cells (final concentration 1.0
mg/mL), and the plate incubated at 37 °C for 4 h. The extent
of resazurin reduction was measured in a microplate reader
(SpectraMax Paradigm, Molecular Devices, Berkshire, UK)
at 570 and 600 nm. For each substance tested, 4 independ-
ent experiments were carried out in quadruplicate. Ethyl
methanesulfonate (30mM) [27] and Triton X-100 (1%) were
used as a positive control. In each experiment, wells with no
test substance added to the culture medium served as un-
treated control (100% viability). Cell viability was determined
according to the following equation:
Viability ¼ A570−A600ð Þsample− A570−A600ð Þblank
A570−A600ð Þcontrol− A570−A600ð Þblank
Cell morphology analysis
Myometrium hTERT-C3 cells and PHM1–41 cells were
stained with fluorescent probes for nuclei (double-
stranded DNA) and cytoplasm (F-actin), as follows. After
treatment with test substances, alone or combined, for
24 h, cells were washed with phosphate buffered saline
(PBS; Gibco, Paisley, UK) and fixed with 4% paraformal-
dehyde (PFA; from Artechemis, Zoffingen, Switzerland)
in PBS for 20 min. Cells were then permeabilised with
0.3% Triton X-100 (Sigma, St. Louis, USA) in 1% bovine
serum albumin (BSA; Sigma, St. Louis, USA) for 30 min.
Then, cells were incubated with a 1:10000 dilution of 4′,
6-diamidino-2-phenylindole (DAPI; Sigma, St. Louis, USA)
and 1:400 rhodamine phalloidin (Invitrogen, Illkirch Cedex,
France) prepared in 0.1% Triton X-100 (Sigma, St. Louis,
USA) in 1% BSA, for 4 h, in the dark. Cells were rinsed with
PBS and examined with the Leica CTR 6000 microscope
(Leica microsystems, Heerbrugg, Switzerland). The entire
procedure was performed at room temperature.
Statistical analyses
Statistical analyses were performed using GraphPad
Prism 7 (GraphPad Software, Inc., CA, USA). In all
cases, a significance level of p < 0.05 was considered sta-
tistically significant.
Because of the slightly different experimental set-ups
used to investigate the combinations of BPJ with atosi-
ban and of BPJ with nifedipine in the myograph model,
different tests were used in the two cases. Data from the
combination of BPJ and atosiban measurements were
analysed with the Kruskal Wallis test followed by Dunn’s
multiple comparisons test. Data from the combination
of BPJ and nifedipine were analysed with the Wilcoxon
test to compare control with BPJ and nifedipine with the
combination (determinations in the same strips, paired
(See figure on previous page.)
Fig. 2 Effect of BPJ, atosiban, and the combination of BPJ with atosiban on human myometrial contractility in vitro. BPJ (green; 15 μL), atosiban
(blue; 4.3 μL of 375 μg/mL) or their combination (red, same concentrations) were added to the myograph chamber. The scatter dot plot shows
the AUC (a), the amplitude (b), and the frequency (c) of contractions expressed as percentage of initial. Krebs solution was used as negative
control (black, 5 μL). Data were obtained from 11 to 15 different biopsies (n = 11–15) and are presented as mean value ± SEM. *p < 0.05
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test), and with the Mann-Whitney to compare control
with nifedipine and with combination (determinations in
different strips, unpaired test). Effects of combination
treatments on myometrial contractility are expressed in
scatter dot plots as mean values ± SEM.
For each test substance, dose-dependency data ob-
tained in the myograph model and cell viability data was
analysed with the paired, non-parametric Friedman test.
Statistical analyses of cell viability data was followed by
Dunn’s multiple comparisons test. In the case of the sin-
gle concentrations of positive controls used in cell viabil-
ity assays, the paired t-test was used to compare their
effects with untreated control. Myograph measurements
on dose-dependency and cell viability data are given as
mean ± SEM.
Results
Effect of BPJ and atosiban on human myometrial
contractility
The exposure of contracting strips to 2.5 μg/mL BPJ and
0.27 μg/mL atosiban (final concentrations in the bath)
led to a decrease of contraction strength (AUC and
amplitude; Fig. 2a and b). BPJ alone lowered the AUC to
70.9 ± 4.7% of initial, which was significantly different
from the control (p = 0.001), while 0.27 μg/mL of atosi-
ban lowered AUC to 80.9 ± 4.1% of initial. When the
combination of BPJ and atosiban was added to the organ
bath, the AUC decreased to 48.8 ± 6.3%, a value signifi-
cantly different from control and atosiban alone (p <
0.001 and p = 0.03, respectively; Fig. 2a).
BPJ decreased the amplitude to 91.0 ± 4.6% of initial,
and atosiban to 93.4 ± 4.6% of initial, but the decreases
were not statistically significant. The combination of BPJ
and atosiban led to a significantly stronger decrease of
amplitude (80.1 ± 7.4% of initial, p = 0.01; Fig. 2b) rela-
tive to control.
The frequency of myometrial contractions increased
with the addition of BPJ to 204.7 ± 27.8% of initial, which
was significantly higher than with atosiban (81.0 ± 10.1%
of initial; p = 0.03). Also, the combination of BPJ and
atosiban led to a significant increase of frequency
(345.4 ± 73.0% of initial) relative to control and atosiban
alone (p = 0.010 and p < 0.001, respectively; Fig. 2c) that
per se did not increase frequency.
Stepwise increase of BPJ and atosiban concentrations
led to successive decreases of myometrial contractility
strength (Fig. 3a and b).
Effect of BPJ and nifedipine on myometrial contractility
BPJ, nifedipine, or the combination of the two led to a
significant decrease of contractions relative to control
(Fig. 4a). BPJ alone lead to a decrease to 78.9 ± 3.8% of
initial (p = 0.003), and nifedipine decreased the AUC to
71.0 ± 3.4% of initial (p < 0.001). The combination of
nifedipine with BPJ had the strongest effect, as the AUC
of contractions was lowered to 39.9 ± 4.6% of initial,
which was significantly different from the effect of ni-
fedipine alone (p < 0.001).
The amplitude of myometrial contractions decreased
with BPJ (91.7 ± 4.7%), nifedipine (86.4 ± 4.4%), and the
combination (65.4 ± 5.3%). Compared to control, the
effect of nifedipine (p < 0.001) and the combination of
BPJ with nifedipine (p = 0.003) was significant. The
combination of BPJ and nifedipine also significantly de-
creased the amplitude when compared to nifedipine
alone (p = 0.002; Fig. 4b).
As shown in Fig. 4c, BPJ strongly increased the frequency
of myometrial contractions to 257.1 ± 40.6% of initial (p <
0.001). In contrast, nifedipine alone had no effect on fre-
quency when compared to control. However, the combin-
ation of BPJ and nifedipine led to an increase of 190.1 ±
22.2% of initial, which was significantly different from
control (p < 0.0001) and from nifedipine alone (p < 0.001;
Fig. 4c).
Exposing the strips to successively higher concentrations
of the combination of BPJ and nifedipine led to stepwise
increases of the inhibitory effects on myometrial contract-
ility (Fig. 3a and b, data on BPJ + Nifedipine).
Effects on myometrial viability
Under our experimental conditions, myometrium strips
were still contracting spontaneously after the washing
step at the end of the myograph experiments, revealing
that the test substances (single or in combinations) were
not toxic to myometrial tissue (data not shown). To
assess the cytotoxicity of the test substances using a
different read-out, viability experiments were performed
with two human myometrial cell lines (hTERT-C3 and
PHM1–41). The test substances, alone or in combin-
ation, were not cytotoxic at similar or even higher con-
centrations than those used in the main combinations
experiment, and at a markedly longer exposure time (24
h; Fig. 5a). At the end of cell viability experiments, cell
morphology was evaluated by fluorescence microscopy.
Visual examination revealed that the test substances did
not affect the morphology of myometrial cells. In
(See figure on previous page.)
Fig. 3 Effect of repeated addition of BPJ plus atosiban (15 μL and 4.3 μL of 375 μg/mL, respectively) and of BPJ plus nifedipine (15 μL and 5 μL of
3.7 μg/mL, respectively) on human myometrial contractility in vitro. All test substances were repeatedly added to the myograph chamber. The
line chart shows the AUC (a), the amplitude (b), and the frequency (c). Data were obtained with 5 different biopsies (n = 5) and are expressed as
percentage of initial. The repeated addition of BPJ was performed for comparison; Krebs solution (5 μL) was used as control. *p < 0.05
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Santos et al. BMC Complementary and Alternative Medicine          (2019) 19:292 Page 8 of 12
(See figure on previous page.)
Fig. 4 Effect of BPJ, nifedipine, and the combination of BPJ with nifedipine on human myometrial contractility in vitro. BPJ (green; 15 μL),
nifedipine (violet; 5 μL of 3.7 μg/mL), or their combination (orange, same concentrations) were added to the myograph chamber. The scatter dot
plot shows the AUC (a), the amplitude (b), and the frequency (c) expressed as percentage of initial. Krebs solution was used as negative control
(black, 5 μL). Data were obtained from 11 to 13 different biopsies (n = 11–13) and are presented as mean value ± SEM. *p < 0.05
Fig. 5 Effect of BPJ, atosiban, nifedipine, BPJ plus atosiban and BPJ plus nifedipine on myometrium cell viability. (a) Cell viability assays were
performed in the presence of BPJ (2.5–10.0 μg/mL), atosiban (0.3–1.1 μg/mL) and nifedipine (3.0–12.0 ng/mL), as well as of BPJ plus atosiban and
BPJ plus nifedipine (same concentrations as with single treatments) using hTERT-C3 and PHM1–41 human myometrium cell lines. Cells were
incubated with the test substances for 24 h. Triton X-100 (1%) and ethyl methanesulfonate (30 mM) were used as positive controls. Data is
presented as mean ± SEM of 4 independent experiments (n = 4), each carried out in quadruplicate; *p < 0.05. (b) Staining of nuclei (blue) and
actin (red) from hTERT-C3 cells untreated (i.e. control) or upon treatment with BPJ (10.0 μg/mL), BPJ plus atosiban (10.0 μg/mL and 1.1 μg/mL,
respectively), and BPJ plus nifedipine (10.0 μg/mL and 12.0 ng/mL, respectively). The images are representative of four independent cultures
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particular, the intact nucleus morphology of hTERT-C3
cells (Fig. 5b) or PHM1–41 cells (data not shown)
treated with the highest concentrations of the various
test substances reveals that the cells were not undergo-
ing apoptosis.
Discussion
Press juice from B. pinnatum leaves, the active ingredient
of chewable tablets that are being used in the management
of preterm labour in Switzerland, enhances the inhibitory
effect of the oxytocin receptor antagonist atosiban on con-
traction strength in human myometrium strips. BPJ also
enhances the effect of nifedipine, a voltage-dependent cal-
cium channel blocker that is in off-label use as a tocolytic.
Both the combination BPJ with atosiban and BPJ with
nifedipine show dose-dependent effects on human myo-
metrial contractility. Reduced viability of myometrial
tissue or cells does not play a role in the observed results.
Taken together, our data corroborate the clinical use of
these combination treatments.
The main strength of our study is the use of the
physiologically most relevant model to study the process
of myometrial contractions in human material, with the
possibility to compare the effect of different substances,
alone and in combination. In fact, our study depicts a
proof of principle for the therapeutic potential of the com-
bination of standard tocolytic medications with BPJ. Alter-
natives would be animal models, but the process of labour
differs between humans and animal species [28, 29]. Limi-
tations of our model are the availability of myometrium
biopsies and the very low throughput that can be achieved
with an organ bath model. For these reasons, the number
of tested concentrations had to be kept low. Also due to
the low throughput, it would be advantageous to further
reduce the variability of results (and therefore of needed
experiments) in future projects. For this reason, two vari-
ant experimental protocols were used in this work. The
comparable SEM values obtained indicated that the two
protocols were equally suited.
Several signalling pathways are known to increase
intracellular calcium concentrations leading to contrac-
tion of myometrium cells. Some of these pathways are
triggered by binding of oxytocin to the corresponding
G-protein coupled receptor, but membrane depolarisa-
tion with concomitant opening of voltage-gated calcium
channels may also play a role [30]. The two tocolytics
used in the present study prevent the increase in intra-
cellular calcium concentration by different mechanisms,
namely by blocking oxytocin receptors in the case of
atosiban, or by blocking voltage-gated calcium channels
in case of nifedipine [11]. Previous work showed that
BPJ inhibits oxytocin-induced increase of intracellular
calcium concentration in myometrium cells. BPJ did not
prevent, but delayed the depolarisation-induced increase
of intracellular calcium in cells with voltage-gated channels
[31]. In myometrial strips, the combination of atosiban with
calcium-channel blockers (nicardipine or nifedipine) led to
additive inhibitory effects, indicating that simultaneous tar-
geting of these two pathways has clinical potential [32, 33].
Therefore, it appears conceivable that the delaying effect of
BPJ on depolarisation-induced increase of intracellular
calcium can enhance the effects of atosiban. Likewise, the
inhibition of oxytocin-induced increase of intracellular cal-
cium concentration by BPJ should synergise with the effects
of nifedipine. To which extent inhibition by BPJ of each of
these two signalling pathways contributes to the observed
in vitro results or to the effectiveness of B. pinnatum prepa-
rations in the treatment of preterm labour is currently not
known.
BPJ is known to increase the contraction frequency of
myometrium strips [19, 20] and this was also observed
in the combination with atosiban or nifedipine (Figs. 2, 3
and 4). Our previous work suggests that various compo-
nents of B. pinnatum leaves might contribute to increase
contraction frequency of myometrium strips [24]. Both a
bufadienolide-enriched fraction and a flavonoid-enriched
fraction (but not the corresponding flavonoid aglycon mix-
ture) seemed to contribute to the frequency increase.
Whether the signalling pathways activated by BPJ might
trigger a partial membrane-depolarisation reserves further
investigations. Trying to translate the increase in frequency
seen in myometrium strips into the clinical situation, we
feel tempted to suggest that B. pinnatum preparations –
but not other tested tocolytics – could induce a type of
conversion of labour-contractions into other, high fre-
quency and painless, and most importantly not-effective,
contractions. These are well known in the praxis, and often
interpreted as myometrium training uterine contractions
that do not lead to labour. In retrospective studies on the
tolerability of B. pinnatum, no clinically relevant increases
of contraction frequency have been observed, neither when
used as single treatment nor in combination with tocolytics
[15–17, 23]. Also, no increase was reported in a prospective
observational study which even included women with uter-
ine tachysystoles [22]. On the contrary, a significant lower-
ing of contraction frequency was observed after 4 h of
treatment with B. pinnatum 50% tablets in a previous ran-
domised trial on acute tocolysis (n = 13) [18].
Although the main combination experiments were
performed in vitro and with concentrations leading to
moderate effects, we compared the concentrations of
atosiban and nifedipine used in vitro with the corre-
sponding plasma concentrations during tocolysis. In the
case of atosiban, the mean plasma concentration at
steady state is 0.44 ± 0.07 μg/mL [34], and in the case of
nifedipine is 67.4 ± 28.4 ng/mL [35]. Therefore, whereas
the concentration of atosiban in the myograph experi-
ments is rather close to that measured in the plasma, the
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concentration of nifedipine was markedly lower. Given
the lack of pharmacokinetic data with BPJ, it is not possible
at this point to compare the concentration in the myograph
experiments with known plasma concentrations.
Currently used standard tocolytic treatments are not
always able to prolong pregnancy for at least 48 h [7]. At
the same time, combinations of standard tocolytics are
not recommended by the Swiss Society for Gynaecology
and Obstetrics current Swiss guidelines [36], nor by the
guidelines from the National Institute for Health and
Care Excellence (NICE) [37] because of concerns about
side-effects. Our data show that BPJ enhances the inhibi-
tory effect of atosiban and nifedipine on myometrium
contractility. In Germany and Switzerland, B. pinnatum
preparations (containing BJP as the active ingredient)
have been used for decades in clinics and private prac-
tices of anthroposophic medicine [15, 16, 38]. In
Switzerland, B. pinnatum preparations are being recom-
mended [21] and used to stop pre-term contractions also
in conventional clinical practice, often as an add-on
treatment [22, 23]. In the case of atosiban, a combin-
ation at low dosages with B. pinnatum would lower the
overall medication costs. As for nifedipine, a lowering of
the dosage in a combination with B. pinnatum would
have the advantage of limiting the well-known cardiovas-
cular side effects, such as palpitations, hypotension,
flushes, headache, and gastro-intestinal symptoms like
gastric upset and constipation [39].
Conclusion
We provide here evidence for the potential of drug com-
binations of atosiban and nifedipine with B. pinnatum.
Such combinations may lower the required dosage of
tocolytics, thereby decreasing treatment costs and redu-
cing maternal and foetal side effects. This could help to
reduce early tocolysis failure and to increase the percent-
age of patients that reach a 48 h delay of delivery. Pro-
spective randomised studies are needed to substantiate
such combination treatments.
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